LeafCann and WardMM Announce Clinical Trial for the Treatment of BPSD
The Next Generation of Medicinal Cannabinoid Therapy with the Integration of Precision Medicine
PRESS RELEASE: Nov 29, 2017
Melbourne, Victoria, Nov 27, 2017 – LeafCann Research and Advisory (LeafCann R&A), announces the signing of a clinical trial agreement with WardMM to sponsor and provide medicinal cannabis extracts for WardMM’s research and development program dedicated to the treatment of behavioural and psychological symptoms of dementia (BPSD). In addition to BPSD, WardMM and LeafCann R&A will focus on developing a foundational medicinal cannabis research and development program to investigate safer medication use with clinically proven outcomes.
This clinical trial will aim to determine evidence based efficacy for the use of medicinal cannabis with healthcare. Person-centred medicine is an approach tailored to each unique individual and condition, utilising identification of individualised biological and pathological differences in the absorption and metabolism of medications and adjusted to target therapeutic objectives.
By integrating WardMM’s diagnostic and decision support platform, this innovative approach will enable clinical trials analysis that address genetic and epigenetic factors, specific patient history and current clinical indications. As the patient is treated, the efficacy of the medication, during and after treatment, is matched and tracked against baselines, and treatment is tailored to minimise treatment complications.
This clinical trial continues LeafCann’s mission to be driven by a person-centred philosophy of healthcare that provides patients and medical professionals with the Gold Standard of efficacy, purity, traceability, transparency and quality control in the development of evidence based medicines. WardMM’s proprietary clinical qualification platform and personalised medicine ethos is a perfect match for LeafCann’s vision for cannabis medicines. Through controlled testing of medicinal cannabis products at LeafCann’s Centre of Excellence, scientists will explore cannabinoid profiling, analytical methodologies and novel medical delivery systems. This comprehensive testing platform will provide the standard for the medicinal cannabis industry in terms of quality control, quality assurance and patient safety.
Dr Jaroslav Boublik, CEO of LeafCann Research & Advisory said “We are delighted to be partnering with WardMM to explore the clinical applications of medicinal cannabis within aged care, in this case specifically, its potential to manage the Behavioural and Psychological Symptoms of Dementia (BPSD). WardMM’s pharmaceutical data management expertise, especially within this sector, represents a substantial advantage over other potential clinical research partners.”
WardMM will conduct its research and development using LeafCann’s medicinal cannabinoid extracts and in partnership with a number of key medical research groups as well as various bioinformatics groups from Australia and the USA.
WardMM Group CEO, Stuart Ward, had this to say about the partnership, “With the use of extensive data, our exciting clinical decision support system and our clinical capability we may be able to reduce the side effects, shape safer medication regimes and provide a better quality of life for patients living with BPSD and their families. We believe cannabinoids will play a vital future role so that patients can have a better quality of life, and safer treatment alternatives available to them.”
LeafCann Group CEO, Elisabetta Faenza stated, “During the last year, our efforts to leverage emerging cannabinoid markets has underlined the need for more clinical research. With our International partners, LeafCann is developing proprietary techniques for managing the genetic expression, cultivation and extraction of active compounds from a variety of medicinal cannabis cultivars, for use in research, human trials, and patient treatment, resulting in integrated personalised medicine.”
WardMM is focusing on clinical decision support for physicians and safer use of medicines. By combining individualised biological results, continuous tracking of medication therapy, understanding therapeutic objectives and applying current technology to health science, the company can provide a greater degree of precision in addressing and predicting the patient’s medical condition on an individual level, both now and into the future. When successful, healthcare providers and patients will be able to identify medications made from specific medicinal cannabis strains that interact best with their individual profiles, resulting in better treatment outcomes.
LeafCann is Australia’s first vertically integrated Gene2Gene Medicinal Cannabis company, leveraging investment and expertise in standardized, environmentally sustainable R&D, cultivation and Supercritical CO2 botanical extraction methodologies. LeafCann is developing a substantial portfolio of research, cultivation and manufacturing assets within Australia to create the basis of a strong local sector, providing Australian patients with access to world first Gold Standard Cannabis Medicines.
Please visit LeafCann’s website:
WardMM is a clinical pharmacist group based in Australia, focused on medication decision support to GPs, providing advisory and risk reduction in the use and administration of medication to the aged care industry and advancing research in clinical pharmacy on the safer use of medication. The aim of WardMM is to end medication related harm through innovation and quality of analyses of medication use and its impact on patients.
Toll Free: 1800 927 366 (WARDMM)